Lembas

What Lembas does

Lembas is a foodtech startup developing bioactive peptide ingredients for the weight management and metabolic health market. Its lead product, Lembas Edge™ (also marketed as GLP-1 Edge), is a patent-pending, food-grade bioactive peptide designed to enhance the body's natural GLP-1 hormone response, with the stated effect of activating satiety signals for 6 to 12 hours. The technology is based on licensed, patent-pending research from Tel Aviv University and is built using an in-house AI-driven computational platform that identifies, designs, and optimizes bioactive peptides for metabolic health applications. The platform is positioned as a pipeline asset intended to extend beyond weight management into adjacent metabolic indications.

The company operates as a B2B ingredient supplier, providing its peptide technology to food, beverage, supplement, and wellness brand customers for integration into consumer products such as bars, shakes, drinks, and supplements. It pursues an enterprise field sales motion, presenting at industry events including Future Food-Tech San Francisco to court CPG partners. Lembas emerged from stealth in June 2025 with a $3.6 million pre-seed funding round led by FLORA Ventures and joined by seven additional investors (Bluestein Ventures, Fresh Fund, Longevity Venture Partners, MAIA Ventures, Siddhi Capital, MANDI, and SHD).

The leadership team is composed of co-founders Shay Hilel (CEO, a serial exited tech/bioinformatics entrepreneur), Dr. Zohar Barbash (CTO, NIH post-doc with FoodTech and pharma R&D experience), Prof. Maayan Gal (CSO, lab head of drug discovery at Tel Aviv University and Harvard Medical School post-doc), and Dr. Daniel Bar (lab head of molecular biology and longevity at Tel Aviv University School of Medicine). The commercial team includes a North America Commercial Lead with F&B and supplement sales experience, and the company is governed by a Founding Chairman (Gil Horsky, Founding Managing Partner of FLORA Ventures and former PepsiCo and Mondelez executive) and an advisory board that includes Prof Arne Astrup, credited with discovering GLP-1's human satiety role and former SVP of the Novo Nordisk Foundation. The company's primary operating geographies for upcoming clinical and commercial activity are the United States and Canada.

Name

Lembas

Legal name

Lembas

Website

https://hellolembas.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Lembas is a foodtech startup that develops patent-pending bioactive peptide ingredients, led by Lembas Edge, which enhances natural GLP-1 response for satiety. It sells B2B to food, beverage, supplement, and wellness brands, with clinical trials beginning in the US and Canada.

Ownership category

akta.pro rank

Product category

Functional Food Ingredients

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG)

akta.pro secondary industries

Protein Hydrolysates & Peptides (Enzymatic Hydrolysates, Bioactive Peptides) (AFAJAHAI), Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids) (CRADAOAJ), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Bioactive peptide ingredients
• Functional food ingredients
• GLP-1 supporting peptides
• Weight management ingredients
• B2B ingredient supplier

Headquarters

HQ city

Sheffield

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

R&D and Technology, Personnel, Operations and Manufacturing

Revenue model

1. Ingredient Sales to CPG Brands: Lembas sells its GLP-1 Edge bioactive peptide ingredient to food, beverage, supplement, and wellness brands for integration into consumer products. The company positions itself as an ingredient supplier to CPG manufacturers looking to develop functional weight management products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Lembas develops and supplies GLP-1 Edge, a patent-pending natural bioactive peptide ingredient designed to support the body's natural GLP-1 hormone response for appetite regulation and weight management. The food-grade peptide mixes easily into bars, shakes, drinks, and supplements, and is positioned as a functional ingredient for CPG brands, supplement manufacturers, and wellness companies seeking scientifically validated weight management solutions. The company combines AI-powered peptide discovery with licensed patent-pending university technology to identify and design bioactive peptides for metabolic health applications.

Product overview

Lembas is pioneering a new category of science-backed supplements and functional ingredients for healthy and effective weight management. The company's primary product is Lembas Edge™, a natural bioactive peptide that supports the body's GLP-1 hormone response to regulate appetite. Built on licensed, patent-pending university technology and powered by AI-driven peptide discovery, Lembas positions itself as a B2B ingredient supplier for supplement, food, beverage, and wellness brands looking to create functional nutrition products for weight management.

Differentiator

Problem solved

Functional benefit

Brands

• Lembas Edge™: Natural bioactive peptide ingredient that enhances the body's natural GLP-1 response for appetite regulation and weight management. Designed to be integrated into bars, shakes, drinks, and supplements.

Products and services

• GLP-1 Edge Bioactive Peptide Ingredient

Quantifiable outcome

• Activates GLP-1 satiety hormones for 6-12 hours

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nuritas: AI-driven bioactive peptide discovery company for food, beverage, and nutraceutical applications. Operates an almost identical business model to Lembas: proprietary AI platform + peptide discovery for CPG ingredient partnerships.
• Brightseed: AI-powered bioactives discovery company targeting metabolic, digestive, and other health areas for CPG and supplement customers. Overlapping AI-bioactives discovery approach, though broader scope than Lembas.
• Shiru: AI-driven discovery platform for natural food ingredients, including proteins and sweeteners, sold B2B to CPG brands. Directly comparable discovery technology and B2B ingredient commercialization model.
• ZBiotics: Engineered-bioactive company making genetically engineered probiotic ingredients for consumer products. Comparable B2B-to-CPG engineered bioactives model, though with probiotics rather than peptides.
• Pendulum: Microbiome-based metabolic health company selling clinically validated probiotics for blood sugar and weight management. Directly competes for the natural metabolic-health consumer, though via probiotics rather than peptides.
• Conagen: Fermentation-based ingredient manufacturer producing peptides, proteins, and specialty ingredients for food, beverage, and supplement customers. Comparable B2B ingredient model with biologically produced peptides.

Broad incumbents

• Ginkgo Bioworks: Large-scale synthetic biology platform designing and manufacturing engineered microbes and ingredients for CPG and industrial customers. A broad incumbent in AI-driven bioactives with vastly larger scale; Lembas's VP Computational Biology is a former Ginkgo (via Zymergen) executive.
• DSM-Firmenich: Global nutrition and ingredient giant with broad functional food, supplement, and metabolic-health ingredient portfolio. Broad incumbent and a likely partner or competitor to Lembas at scale.
• Ingredion: Major specialty ingredient supplier serving food, beverage, and nutrition customers with proteins, fibers, and functional ingredients. Broad incumbent that could partner with or compete against Lembas in functional food peptides.
• Kerry Group: Global taste and nutrition ingredient company supplying functional and health-positioned ingredients to CPG customers. Broad incumbent with comparable B2B CPG distribution channels for functional ingredients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hellolembas

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lembas